Sandoz Enbrel biosim cruises at FDA panel, endangering key Amgen sales


In the second straight resounding vote in favor of a biosimilar in as many days, Sandoz’s version of Amgen’s Enbrel earned unanimous support from an FDA panel Wednesday.

With the 20-0 vote, Novartis’ generics unit advances in its crusade toward a potential big sales boost and a second biosim on the U.S. market that’s just getting acquainted with the biosimilar concept. Dubbed GP2015, Sandoz’s Enbrel biosim looks “highly similar” to the original product, FDA staffers said earlier this week, and could now be in a position to take a big bite out of the California company’s $5.1 billion in sales from its anti-TNF blockbuster.

Prior to the meeting, FDA staffers said they considered there to be “sufficient scientific justification” in extrapolating psoriasis biosimiliarity data to other indications Sandoz is seeking in rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis, they said. The committee agreed, recommending the biosim for all of Enbrel’s approved indications. The FDA doesn't always follow committee recommendations, but it typically does.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Wednesday’s meeting represented the second straight day an FDA expert committee unanimously supported a biosimilar following Tuesday’s vote in favor of Amgen’s copy of AbbVie rheumatoid arthritis megablockbuster Humira. This time, though, it’s Amgen fending off biosimilar competition while Sandoz inches forward in the field.

The Swiss pharma’s generics outfit is betting big in biosims, saying recently it’s shooting to market 5 by 2020 in the U.S. and other “key geographies.” It’s planning to submit 11 regulatory filings by the end of 2017 and expects to gain approval for copies of Enbrel, Humira, Neulasta from Amgen, Remicade from Johnson & Johnson and Merck, and Rituxan from Roche. The company is already blazing a path with the first U.S.-approved biosim in Zarxio, a copy of Amgen’s Neupogen.

- here's Sandoz's release

Related Articles:
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's Enbrel
Novartis' Sandoz aims for 5 biosim launches by 2020
Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do?
In unanimous vote, FDA committee backs Amgen's Humira biosim


Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.